---
document_datetime: 2023-09-21 21:08:40
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/optison-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: optison-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 29.8155028
conversion_datetime: 2025-12-21 16:51:33.195938
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Optison

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IAIN/0075/G          | This was an application for a group of variations.                                               | 27/06/2022                          | n/a                                         |                                  |           |
| N/0074               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 19/05/2022                          |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| N/0072      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 04/10/2021   |     | PL   |                                   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|------|-----------------------------------|
| IAIN/0070/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - updated/amended PMF when changes | 16/06/2021   | n/a |      | Inclusion of an do not affect the |
| IA/0071     | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 15/06/2021   | n/a |      |                                   |
| IA/0069/G   | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 05/11/2020   | n/a |      |                                   |

<div style=\"page-break-after: always\"></div>

|                    | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                    |            |     |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IAIN/0068          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                  | 08/07/2020 | n/a |                                   |
| IA/0067/G          | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                             | 04/02/2020 | n/a |                                   |
| IAIN/0066/G        | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 08/11/2019 | n/a |                                   |
| PSUSA/2350/ 201812 | Periodic Safety Update EU Single assessment - perflutren                                                                                                                                                                                                                                                                                                        | 05/09/2019 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IAIN/0064   | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                                                                                            | 15/08/2019   | n/a        |                                  |                            |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|----------------------------|
| IAIN/0065/G | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes | 14/08/2019   | n/a        |                                  | do not affect              |
| IB/0062/G   | This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                                                                                  | 09/11/2018   | 21/10/2019 | SmPC, Annex II, Labelling and PL | C.I.z - Changes Veterinary |
| IAIN/0061   | B.V.a.1.d - PMF - Inclusion of a new, updated or                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 26/06/2018   | n/a        |                                  |                            |

<div style=\"page-break-after: always\"></div>

|           | PMF in the marketing authorisation dossier a medicinal product. (PMF 2nd step procedure) - of an updated/amended PMF when changes not affect the properties of the FP                                                                                                                                                                                                                                                                    |            |     | amended of Inclusion do    |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------|
| IB/0060   | B.V.a.1.b - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - First-time inclusion of a new PMF NOT affecting the                                                                                                                                                                                                                               | 24/04/2018 | n/a | properties of the FP       |
| IB/0059/G | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold | 31/08/2017 | n/a | compared to the originally |
| IAIN/0058 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                                                                                                                           | 28/04/2017 | n/a |                            |
| IB/0056   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                                                                                                                                                                                            | 02/03/2017 | n/a |                            |

<div style=\"page-break-after: always\"></div>

|                    | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                 |            |     |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IA/0055/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                  | 28/02/2017 | n/a |                                   |
| IAIN/0057          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 27/02/2017 | n/a |                                   |
| PSUSA/2350/ 201512 | Periodic Safety Update EU Single assessment - perflutren                                                                                                                                                                                       | 02/09/2016 | n/a | PRAC Recommendation - maintenance |
| IAIN/0054          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP | 14/06/2016 | n/a |                                   |
| IAIN/0052          | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes                                        | 13/05/2015 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | do not affect the properties of the FP                                                                                                                                                                                                                                                                                                |            |            |      |                     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|---------------------|
| IA/0051   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                         | 20/10/2014 | n/a        |      |                     |
| IA/0050/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the of a supplier | 10/09/2014 | n/a        |      | dossier) - Deletion |
| IB/0049   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                        | 08/05/2014 | 04/07/2014 | SmPC |                     |
| IAIN/0048 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP                                                                                        | 14/04/2014 | n/a        |      |                     |
| IAIN/0047 | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the                                                                                                                                                                                     | 30/10/2013 | n/a        |      | PSMF location       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IAIN/0046/G   | This was an application for a group of variations. B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP   | 28/08/2013   | n/a   |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IAIN/0045     | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/08/2013   | n/a   |

<div style=\"page-break-after: always\"></div>

|           | a medicinal product. (PMF 2nd step procedure) - of an updated/amended PMF when changes not affect the properties of the FP                                                                                                                                                                                                                                                                                                                                          |            |            |                                  | of Inclusion do        |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|------------------------|
| IB/0043/G | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of | 26/07/2013 | n/a        |                                  | an obsolete parameter) |
| IB/0044   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                      | 24/07/2013 | 04/07/2014 | SmPC, Annex II, Labelling and PL |                        |
| IA/0041/G | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                          | 03/07/2013 | n/a        |                                  | B.II.d.1.a -           |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | and/or limits of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| II/0039/G | This was an application for a group of variations. This was an application for a group of variations to add a manufacturing site for the drug product, and to make changes to the drug product manufacturing process, batch size and in-process tests and limits. B.II.a.3.b.6 - Changes in the composition (excipients) of the finished product - Other excipients - Replacement of a single excipient with a comparable excipient with the same functional characteristics and at a similar level B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.3.b - Change in the manufacturing process of | 30/05/2013 | n/a |

<div style=\"page-break-after: always\"></div>

|         | manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the currently approved batch size B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new tests and limits B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0040 | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 05/04/2013 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0037 | Update of section 4.2 and 5.1 of the Summary of Product Characteristics (SPC) further to the request of the CHMP following the assessment of paediatric data submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended (P45- 012). C.I.3.b - Implementation of change(s) requested                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 18/11/2010 | 20/12/2010 | SmPC and PL | In accordance with Article 45 of the Paediatric Regulation 1901/2006, the Marketing Authorisation Holder (MAH) submitted available paediatric data. Following the assessment of these paediatric data, the CHMP concluded that although demonstrating an effect that appears to be similar to that seen in adults, the submitted study does not allow any conclusions on posology in children and adolescents. |

<div style=\"page-break-after: always\"></div>

|         | following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                |            |     |             | However, safety data is available in 42 children, aged 8 months to 19 years. The data indicate that the safety profile of Optison is similar in this age group when compared to adults. This information could be of use to the prescriber and CHMP recommended that sections 4.2 and 5.1 were amended with these observations.                                                                                                   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0038 | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                 | 18/11/2010 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IB/0036 | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH | 20/09/2010 | n/a | SmPC and PL | To include nausea and tachycardia in section 4.8 in the SmPC as common and rare adverse reactions respectively. The PL has been updated accordingly. Furthermore section 4.6 was updated according to QRD to include Fertility in the heading.                                                                                                                                                                                    |
| IB/0035 | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH | 20/09/2010 | n/a | SmPC and PL | To update SPC and PL to include warning on transmissible agents. Also section 4.4 and PL were updated to include wording required for albumin. Furthermore the MAH applied to update the addresses of local representatives for Sweden, Spain, Greece, Belgium, Luxembourg and Denmark and to add the statement that \"Not all pack size may be marketed\" in section six of the PL to reflect the text already present in the SPC. |
| IA/0034 | B.V.a.1.d - PMF - Inclusion of a new, updated or amended PMF in the marketing authorisation dossier of a medicinal product. (PMF 2nd step procedure) - Inclusion of an updated/amended PMF when changes do not affect the properties of the FP             | 19/05/2010 | n/a |             |                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| 2PMF/0033   | Inclusion of the updated or amended Plasma Master File (CSL Behring EMEA/H/PMF/000001/04) in the marketing authorisation dossier   | 15/12/2009   | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------|------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Z/0032      |                                                                                                                                    | 25/06/2009   | 08/10/2009 |                                  | Please refer to Assessment Report (Optison-H-166-Z-32- AR) for further information.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| R/0031      | Renewal of the marketing authorisation.                                                                                            | 19/03/2008   | 12/06/2008 | SmPC, Annex II, Labelling and PL | Based on the CHMP review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Optison continues to be favourable. The CHMP was also of the opinion that the renewal can be granted with unlimited validity. However, due to limited exposure and in light of the ongoing discussions with the US FDA regarding the changes to the USPI in the context of the safety concern on micro-bubble contrast agents, the CHMP is of the opinion that the MAH should continue to provide annual PSURs. Notwithstanding the above, the CHMP noted that the MAH was not able to present an authorised importer for Optison to ensure the supply of the medicinal product at the EU/EEA market and to proof GMP compliance of the manufacturing process at the US manufacturing site at the time of this Renewal. Therefore, the CHMP recommends that the marketing authorisation of Optison should be suspended. The following changes were included to Section 4.4 and Section 4.8 of the SPC including corresponding changes to the package leaflet: |

<div style=\"page-break-after: always\"></div>

|          |                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                                  | hypersensitivity was made broader and is no longer linked to human albumin and protein allergy. Furthermore, the recommended time for monitoring of severely ill patients with certain conditions (with cardiac, pulmonary, renal, hepatic diseases) was extended to during and after administration of Optison. Finally, a recommendation to use end-diastolic triggering to avoid biological side effects of the contrast agent due to interaction with the ultrasound beam was included. In the Section 4.8, the term anaphylactoid shock was included.   |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MF/0030  | 2PMF (2nd step of PMF certification procedure)                                                                                                                                                                                                                                                                                                                                                                  | 17/10/2007 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| N/0029   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                | 09/10/2006 | n/a        | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| IA/0028  | IA_01_Change in the name and/or address of the marketing authorisation holder IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                                 | 09/10/2006 | n/a        | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| A20/0027 | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 11 April 2006 the opinion of the Committee for Medicinal Products for Human Use (CHMP) on whether further action is necessary with respect to OPTISON, in the light of a Class I Rapid Alert and subsequent suspension of the import authorisation of the manufacturer responsible for batch release in the EU/EEA. | 01/06/2006 | 07/08/2006 |                                  | Decision: To maintain the MA following untoward findings of a GMP inspection of the manufacturing site.                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IB/0026   | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                            | 10/05/2005   | n/a        |                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|
| N/0025    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                              | 14/02/2005   | n/a        | Labelling and PL                 |
| II/0024   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                              | 23/06/2004   | 12/08/2004 | SmPC and PL                      |
| II/0023   | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                | 25/09/2003   | 26/09/2003 |                                  |
| R/0022    | Renewal of the marketing authorisation.                                                                                                                                       | 20/02/2003   | 15/05/2003 | SmPC, Annex II, Labelling and PL |
| I/0021    | Change in manufacturing site for outer packaging and batch release in the EEA. 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process | 15/01/2003   | 17/03/2003 | Annex II and PL                  |
| II/0020   | Change(s) to the manufacturing process for the finished product Update of Summary of Product Characteristics and Package Leaflet                                              | 19/09/2002   | 20/11/2002 | SmPC, Labelling and PL           |
| T/0019    | Transfer of Marketing Authorisation                                                                                                                                           | 19/03/2002   | 29/04/2002 | SmPC, Labelling and              |

<div style=\"page-break-after: always\"></div>

|        |                                                                                                                                                                                                                                                                                                                                                              |            |            | PL                     |                            |
|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------|
| N/0018 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                             | 13/03/2002 | 18/04/2002 | PL                     |                            |
| I/0015 | 01_Change following modification(s) of the manufacturing authorisation(s)                                                                                                                                                                                                                                                                                    | 17/01/2002 | 07/02/2002 |                        |                            |
| I/0016 | 02_Change in the name of the medicinal product (either invented name of common name)                                                                                                                                                                                                                                                                         | 14/05/2001 | n/a        | SmPC, Labelling and PL |                            |
|        | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                                                                                                                             | 27/07/2000 | 29/11/2000 | SmPC and PL            | II/0011                    |
| I/0014 | 01_Change in the name of a manufacturer of the medicinal product                                                                                                                                                                                                                                                                                             | 09/08/2000 | 14/08/2000 |                        |                            |
| I/0013 | Authorisation Holder applied for the use of an alternative rubber stopper for the 3 ml cartridge and for an extension of the shelf life of the finished product as packaged for sale, from 2 years to 3 years, for the current and proposed alternative container closure system of the 3 ml cartridge presentations. specification of the medicinal product | 30/05/2000 | n/a        |                        | The Marketing 17_Change in |
| I/0012 | 12_Minor change of manufacturing process of the active substance                                                                                                                                                                                                                                                                                             | 26/05/2000 | 29/05/2000 |                        |                            |
| I/0010 | 15_Minor changes in manufacture of the medicinal                                                                                                                                                                                                                                                                                                             | 08/05/2000 | 12/05/2000 |                        |                            |

<div style=\"page-break-after: always\"></div>

|        | product                                                                                              |            |            |    |
|--------|------------------------------------------------------------------------------------------------------|------------|------------|----|
| I/0009 | 19_Change in specification of excipients in the medicinal product (excluding adjuvants for vaccines) | 08/05/2000 | 12/05/2000 |    |
| N/0008 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)     | 27/01/2000 | 23/10/2000 | PL |
| I/0007 | 11b_Change in supplier of an intermediate compound used in manufacture of the active substance       | 19/08/1999 | 23/09/1999 |    |
| N/0005 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)     | 18/05/1999 | 29/06/1999 | PL |
| I/0006 | 15a_Change in IPCs applied during the manufacture of the product                                     | 04/05/1999 | n/a        |    |
| I/0004 | 17_Change in specification of the medicinal product                                                  | 18/12/1998 | 02/03/1999 |    |
| I/0002 | 01_Change following modification(s) of the manufacturing authorisation(s)                            | 05/11/1998 | n/a        |    |
| N/0001 | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)     | 23/09/1998 | 19/11/1998 | PL |